How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-03-20
DOI
10.3389/fimmu.2020.00492
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
- (2019) Akinori Sasaki et al. Gastric Cancer
- Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
- (2019) David Cella et al. LANCET ONCOLOGY
- Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series
- (2019) Daniel Jiahao Wong et al. Immunotherapy
- Nivolumab-refractory patients with advanced non-small-cell lung cancer
- (2019) A. Costantini et al. LUNG CANCER
- PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
- (2019) Takahiro Kamada et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
- (2019) Zhi Ji et al. BMC CANCER
- Hyperprogression as a Distinct Outcome after Immunotherapy
- (2018) J. Fuentes-Antrás et al. CANCER TREATMENT REVIEWS
- Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
- (2018) M. Tazdait et al. EUROPEAN JOURNAL OF CANCER
- Pseudoprogression and hyperprogression after checkpoint blockade
- (2018) Qiaohong Wang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC
- (2018) Pedro Rocha et al. Journal of Thoracic Oncology
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired resistance to cancer immunotherapy
- (2018) Arianna Draghi et al. Seminars in Immunopathology
- Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
- (2018) Francesco Soria et al. WORLD JOURNAL OF UROLOGY
- Tumor-derived exosomes induce PD1+ macrophage population in human gastric cancer that promotes disease progression
- (2018) Furong Wang et al. Oncogenesis
- Hyperprogressive Disease in Anorectal Melanoma Treated by PD-1 Inhibitors
- (2018) Marjorie Faure et al. Frontiers in Immunology
- Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
- (2018) Michäel Duruisseaux et al. Lancet Respiratory Medicine
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
- (2018) Roberto Ferrara et al. JAMA Oncology
- LBA1Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC
- (2018) D R Gandara et al. ANNALS OF ONCOLOGY
- Frontline immunotherapy treatment with nivolumab and ipilimumab in metastatic renal cell cancer: a new standard of care
- (2018) Amanda Nizam et al. CANCER BIOLOGY & THERAPY
- Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism
- (2018) David A. Knorr et al. CLINICAL CANCER RESEARCH
- Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
- (2018) Julia L. Boland et al. GYNECOLOGIC ONCOLOGY
- Genome-wide sequencing of cell-free DNA identifies copy number alterations that can be used for monitoring response to immunotherapy in cancer patients
- (2018) Taylor J Jensen et al. MOLECULAR CANCER THERAPEUTICS
- The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent
- (2018) Chloé Grasselly et al. Frontiers in Immunology
- Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
- (2018) Giuseppe Lo Russo et al. CLINICAL CANCER RESEARCH
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy
- (2017) Maximilian J. Hochmair et al. LUNG CANCER
- The expanding role of innate lymphoid cells and their T-cell counterparts in gastrointestinal cancers
- (2017) Ka Yee Fung et al. MOLECULAR IMMUNOLOGY
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Immunotherapy for Colorectal Cancer
- (2017) Patrick Boland et al. Cancers
- Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions
- (2017) Shilpa Gupta et al. Cancers
- Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting
- (2016) Julie E. Bauman et al. CANCER
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- (2016) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
- (2016) Douglas G. McNeel et al. Journal for ImmunoTherapy of Cancer
- P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma
- (2015) A. Ribas et al. EUROPEAN JOURNAL OF CANCER
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic
- (2015) Mark A. Socinski SEMINARS IN ONCOLOGY
- NCR+ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures
- (2015) Paolo Carrega et al. Nature Communications
- Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment
- (2015) J. V. Cohen et al. Cancer Immunology Research
- Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model
- (2013) Stefanie Kirchberger et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
- (2013) Paolo A Ascierto et al. Journal of Translational Medicine
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
- (2013) Howard L. Kaufman et al. Nature Reviews Clinical Oncology
- Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma
- (2013) C. A. Barker et al. Cancer Immunology Research
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Pseudoprogression and pseudoresponse in the treatment of gliomas
- (2009) Dieta Brandsma et al. CURRENT OPINION IN NEUROLOGY
- Special regulatory T cell review: The resurgence of the concept of contrasuppression in immunoregulation
- (2008) Thomas Lehner IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More